Management of Hypertension in Patients with End-Stage Renal Disease on Hemodialysis

Introduction to Hypertension Management

• The American Heart Association recommends intensifying antihypertensive therapy in patients with coronary artery disease and heart failure with reduced ejection fraction, with a goal of reducing mortality 1, 2

Rationale for Beta-Blocker Optimization

• Beta-blockers provide a dual benefit in patients with coronary artery disease and heart failure with reduced ejection fraction, reducing both blood pressure and mortality 1, 2
• The American College of Cardiology recommends optimizing beta-blocker therapy, such as increasing carvedilol to a maximum tolerated dose of 50 mg twice daily, as a first step in managing hypertension in these patients 1, 2

Blood Pressure Targets

• The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend a predialysis blood pressure goal of <140/90 mmHg for hemodialysis patients, measured in the sitting position, to minimize left ventricular hypertrophy and mortality 2
• The American Heart Association suggests considering a lower blood pressure target of <130/80 mmHg in patients with coronary artery disease and heart failure, if tolerated, while avoiding diastolic blood pressure <65 mmHg to prevent worsening myocardial ischemia 1, 4

Stepwise Approach to Hypertension Management

• The European Society of Cardiology recommends a stepwise approach to managing hypertension in patients with end-stage renal disease on hemodialysis, starting with optimization of beta-blocker therapy, followed by increase of amlodipine to 10 mg daily if necessary, and then addition of a loop diuretic to achieve optimal dry weight 1, 2, 4, 5

Critical Monitoring Parameters

• The American Heart Association recommends monitoring orthostatic vital signs, symptomatic hypotension, and volume status, as well as assessing dry weight with the nephrology team, to ensure safe and effective blood pressure management in hemodialysis patients 1, 2, 4

Medications to Avoid

• The American College of Cardiology advises against using non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, in patients with heart failure due to their negative inotropic effects and risk of worsening heart failure 4
• The European Society of Cardiology recommends avoiding alpha-blockers, such as doxazosin and prazosin, unless all other options are exhausted, as they increase the risk of heart failure 4